CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a DNA vaccine for visceral leishmaniasis, utilizing established antigens and immunomodulators. It will evaluate the vaccine's efficacy in preclinical models and prepare for clinical trials to combat this disease.
This project will focus on the preclinical development of a DNA vaccine for human visceral leishmaniasis.
The project is based upon the DNA vaccine technology and immunomodulators developed at Mologen AG (Berlin, Germany), which are in clinical development for cancer and 3-5 known antigens that already have demonstrated profiles of protection in animal models of leishmaniasis.
Antigens will be selected on the basis of preset criteria to assure protection in high proportion of target populations…
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, BERLIN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Germany, Berlin
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
